359 studies found for:    "Alkylating Agents" | updated in the last 30 days
Show Display Options
Rank Status Study
1 Recruiting Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
2 Terminated MT2004-30: Tomotherapy for Solid Tumors
Conditions: Brain and Central Nervous System Tumors;   Kidney Cancer;   Liver Cancer;   Retinoblastoma;   Sarcoma
Interventions: Biological: filgrastim;   Drug: busulfan;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: thiotepa;   Procedure: stem cell transplantation;   Radiation: tomotherapy;   Radiation: total marrow irradiation;   Drug: Mesna;   Radiation: Whole lung radiation
3 Recruiting Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Conditions: Hematopoietic Stem Cell Transplantation;   Solid Tumor;   Transplantation, Autologous
Interventions: Drug: Ifosfamide;   Drug: Etoposide phosphate;   Drug: Mesna;   Biological: Granulocyte colony-stimulating factor;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation;   Drug: Caboplatin
4 Completed Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer (Excluding Squamous Cell)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Carboplatin
5 Recruiting Ph 3 Trial of Blinatumomab vs Investigator's Choice of Chemotherapy in Patients With Relapsed or Refractory ALL
Condition: Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Interventions: Drug: Blinatumomab;   Drug: Standard of Care Chemotherapy
6 Recruiting Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
Condition: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer
Interventions: Drug: AZD1775;   Drug: AZD1775 Matching Placebo;   Drug: pemetrexed;   Drug: carboplatin
7 Recruiting Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers
Condition: Squamous Cell Lung Cancer
Interventions: Drug: Apatorsen (OGX-427);   Drug: Gemcitabine;   Drug: Carboplatin
8 Recruiting Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.
Condition: Diffuse, Large B-Cell, Lymphoma
Interventions: Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Vincristine
9 Recruiting Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma
Conditions: Stage II Childhood Hodgkin Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage IV Childhood Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: etoposide;   Drug: prednisone;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: Dacarbazine(R);   Drug: filgrastim;   Other: quality of life assessment;   Radiation: radiation therapy
10 Recruiting Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Conditions: Leukemia, Acute Lymphocytic (ALL);   Leukemia, Myeloid, Acute(AML);   Leukemia, Myeloid, Chronic(CML);   Juvenile Myelomonocytic Leukemia (JMML);   Hemoglobinuria, Paroxysmal Nocturnal (PNH);   Hodgkin Lymphoma;   Lymphoma, Non-Hodgkin (NHL);   Myelodysplastic Syndrome (MDS)
Interventions: Device: CliniMACS;   Procedure: Stem cell transplantation;   Drug: Fludarabine;   Drug: Thioplex®;   Drug: L-phenylalanine mustard;   Drug: Mycophenolate mofetil;   Drug: Rituxan™;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Anti-thymocyte globulin (Rabbit);   Drug: G-CSF
11 Recruiting Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Conditions: Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
Interventions: Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
12 Completed
Has Results
Effects of Exercise in Combination With Epoetin Alfa
Condition: Multiple Myeloma
Interventions: Drug: Epoetin Alfa;   Behavioral: Exercise;   Biological: Autologous Peripheral Blood Stem Cell Transplantation;   Biological: Red Blood Cell Transfusion;   Drug: Thalidomide;   Drug: Heparin, Low-Molecular-Weight;   Biological: Platelet Transfusion;   Drug: Melphalan;   Drug: Total Therapy II
13 Active, not recruiting Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
14 Recruiting Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis
Condition: Germ Cell Tumors
Interventions: Drug: Paclitaxel;   Drug: Ifosfamide;   Drug: Carboplatine;   Drug: Etoposide;   Procedure: cytapheresis + transfusion of autologous peripheral blood stem cells
15 Recruiting Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen
Condition: Lymphoma, Follicular
Interventions: Drug: Ofatumumab and Bendamustine infusions (Arm A);   Drug: Bendamustine infusion (Arm B)
16 Recruiting A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine;   Drug: Obinutuzumab
17 Active, not recruiting A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Condition: Glioma
Interventions: Drug: LY2157299;   Drug: Lomustine
18 Active, not recruiting Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)
Condition: Malignant Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Dacarbazine;   Drug: Temozolomide
19 Completed Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: tipifarnib;   Drug: temozolomide;   Radiation: radiation therapy
20 Recruiting Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis
Conditions: Leukemia;   Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Severe Aplastic Anemia;   Allogeneic Transplant
Intervention: Drug: Cyclophosphamide

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years